RUNX2 and nonpapillary renal cell carcinoma: Survival analysis using TCGA clinical data showed that ccRCC patients with high expression of Runx2 had shorter overall survival and disease-free survival than patients with low level of Runx2 (P < 0.001, Figs. 1E and S1).